The landscape of nuclear medicine in 2026 is defined by a significant transition toward decentralized, hospital-based radiopharmaceutical production. A detailed Medical Cyclotron Market analysis shows that the industry is rapidly moving away from a total reliance on central nuclear reactors, favoring on-site particle accelerators that offer real-time access to diagnostic tracers. This evolution...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt